Table 1.
Clinicopathological characteristics of the entire cohort and subgroups according to AST/ALT ratio (AST/ALT ratio <1.23 are low group, otherwise high group) before propensity score matching
| Characteristics | Entire cohort | Low AST/ALT | High AST/ALT | P-value |
|---|---|---|---|---|
| Number of Subjects | 885 | 353 | 532 | |
| Preoperative characteristics | ||||
| Age, years | 66.98±10.55 | 64.07±10.93 | 69.04±9.60 | <0.001 |
| Aged >65 years | 575 (65.0%) | 187 (53.0%) | 388 (73.0%) | <0.001 |
| Gender (male) | 396 (44.7%) | 195 (55.2%) | 158 (29.7%) | <0.001 |
| BMI | 24.25±3.53 | 25.06±3.45 | 23.70±3.46 | <0.001 |
| Diabetes | 134 (15.1%) | 60 (17.0%) | 74 (13.9%) | 0.126 |
| Hypertension | 333 (37.6%) | 130 (36.8%) | 203 (38.1) | 0.946 |
| Coronary disease | 99 (11.2%) | 30 (8.5%) | 69 (13.0%) | 0.060 |
| Alcohol | 98 (11.1%) | 51 (14.4%) | 47 (8.8%) | 0.009 |
| Tobacco | 138 (15.6%) | 68 (19.3%) | 70 (13.2%) | 0.014 |
| Hydronephrosis | 427 (48.2%) | 158 (44.8%) | 269 (50.6%) | 0.233 |
| Tumor location (pelvis) | 474 (53.6%) | 187 (53.0%) | 287 (53.9%) | 0.776 |
| Tumor size (>5 cm) | 94 (10.6%) | 25 (7.1%) | 69 (13.0%) | 0.011 |
| Postoperative characteristics | ||||
| Pathological T Stage | 0.832 | |||
| Ta | 6 (0.7%) | 1 (0.3%) | 5 (0.9%) | |
| T1 | 322 (36.4%) | 130 (36.8%) | 192 (36.1%) | |
| T2 | 295 (33.3%) | 116 (32.9%) | 179 (33.6%) | |
| T3 | 238 (26.9%) | 96 (27.2%) | 142 (26.7%) | |
| T4 | 24 (2.7%) | 10 (2.8%) | 14 (2.6%) | |
| Pathological N Stage | 0.081 | |||
| N0 | 823 (93.0%) | 331 (93.8%) | 492 (92.5%) | |
| N1 | 57 (6.4%) | 18 (5.1%) | 39 (7.3%) | |
| N2 | 5 (0.6%) | 4 (1.1%) | 1 (0.2%) | |
| Cellular grade | 0.286 | |||
| G1 | 25 (2.8%) | 12 (3.4%) | 13 (2.4%) | |
| G2 | 493 (55.7%) | 205 (58.1%) | 288 (54.1%) | |
| G3 | 367 (41.5%) | 136 (38.5%) | 231 (43.4%) | |
| Lymphatic microvascular invasion | 46 (5.20%) | 17 (4.8%) | 29 (5.5%) | 0.677 |
| Tumor major diameter | 3.46±2.26 | 3.33±2.29 | 3.55±2.23 | 0.160 |
| Tumor necrosis | 114 (12.9%) | 43 (12.2%) | 71 (13.3%) | 0.613 |
| Tumor hemorrhage | 28 (3.2%) | 9 (2.5%) | 19 (3.6%) | 0.395 |
| Tumor architecture (sessile) | 161 (18.2%) | 59 (16.7%) | 102 (19.2%) | 0.587 |
| Squamous metaplasia | 85 (9.6%) | 29 (8.2%) | 56 (10.5%) | 0.253 |
| Sarcomatoid differentiation | 34 (3.8%) | 12 (3.4%) | 22 (4.1%) | 0.577 |
| Glandular differentiation | 39 (4.4%) | 15 (4.2%) | 24 (4.5%) | 0.716 |